Head-to-head · WeighScore
Belle Health vs NovoCare Pharmacy
The verdict
Belle Health takes it — 77/100 to 55.2/100.
Belle Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Belle Health is a national DTC telehealth platform offering compounded semaglutide and tirzepatide with flat-rate pricing — the same monthly cost at every dose, with no escalation surcharge as you titrate up.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | NovoCare Pharmacy |
|---|---|---|
| WeighScore | 77/100 | 55.2/100 |
| Grade | C+ | C |
| Scorecard rank | #48 | #442 |
| Semaglutide | $119/mo | $349/mo (2.4 mg dose, brand-name) |
| Tirzepatide | $199/mo (all doses, 3-month plan, compounded) | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #48 · C+
Strengths
- Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
- Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
- Free weekly registered-dietitian sessions included
- Operating since 2017
- LegitScript Certified
Where it loses points
- $199 tirzepatide price requires a 3-month bundle commitment
- Compounded medications are not FDA-approved
- Multi-pharmacy model — formulations may differ across orders
- FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Graded #442 · C
Strengths
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
Where it loses points
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.